Gilead ’s stock tumbles toward biggest selloff in more than 9 years after lung cancer treatment trial disappoints
Shares of Gilead Sciences Inc. GILD, tumbled 10.9% beating in premarket trading Monday, to pullback from an 11-month high, after the biotechnology company disappointing trial results of its lung cancer treatment. That selloff would put the stock in danger of the biggest one-day decline since it…#gileadsciencesinc #gild #nsclc #gilead #trodelvy #merdadparsey
Source: Reuters: Health - Category: Consumer Health News Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Health | Lung Cancer | Non-Small Cell Lung Cancer